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Abstract: 
Objective: To determine mean serum vitamin B12 levels in patients with type II diabetes mellitus using 
metformin. 
Study Design: Prospective Cross sectional Study Location and Duration: Department of Medicine, Nishtar 
Hospital Multan, from March 2018 to September 2019. 
Methodology: 
Ninety two patients were involved after getting informed consent. HbA1c, body mass index and blood pressure 
and deficiency for vitamin B12 was assessed by using electro-chem-iluminescence immunoassay method. B12 
levels were categorized as normal (>220pg/ml), possibly deficient (150 to 220 pg/ml) and definitely deficient 
(<150pg/ml). Neuropathy was assessed and was classified by using Toronto clinical scoring system by the 
researcher himself. All the data was subjected to statistical analysis using computer software SPSS version 23. 
Continuous variables were analyzed by their mean and standard deviation while quantitative variables were 
analyzed by frequency and percentages. Chi square test was applied and P value less than or equal to 0.05 was 
taken as significant. 
Results: Mean Serum B-12 levels were 378.42±161.27 pg/ml and 488.90±147.02 pg/ml in metformin and non-
metformin groups, respectively. The difference was statistically significant (p=0.001). The patients who were 
possibly deficient and definitely deficient were 15 (28.30%) and 5 (9.43%) in metformin group and were 
significantly more (p=0.006) than non-metformin group i.e. 4 (10.26%) and 0. The mean Toronto Neuropathy 
Score was statistically different (p<0.001) between metformin group (6.03±1.73) and non-metformin group 
(4.13±1.75). The patients who had mild neuropathy and moderate neuropathy were 23 (43.39%) and 5 (9.43%) 
in metformin group, while 6 (15.38%) and 2 (5.13%) in non-metformin group. Statistically, both the groups were 
significantly different (p=0.005). 
Conclusion: At the end of this study conclusion can be made that metformin use for type II diabetes mellitus is 
strongly associated with vitamin B12 deficiency and worsening of already susceptible neuropathy.  
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Introduction: 
For almost forty years it has been known that metformin use has a hand in lowering vitamin B12 levels. Vitamin 
B12 deficiency is a common phenomenon among the elderly 1. Clinically it may present as hematological 
disease or neuropsychiatric illness and at times it is difficult to detect in certain scenarios 2. Usually vitamin B12 
deficiency is basically caused by malabsorption leading to classical condition of pernicious anemia. Two case 
reports have been found which showed evidence of vitamin B12 deficiency causing peripheral neuropathy 3 and 
in the light of these reports annual supplementation of vitamin B12 has been recommended for the patient 
receiving metformin for type II diabetes mellitus. In some parts of the world it is now considered as an empirical 
therapy for peripheral neuropathy. 
Metformin is one of the first line drugs in the treatment of patients with type II diabetes mellitus 4 and is 
associated least no. of side effects. It is strictly anti-hyperglycemic and also reduces the overall morbidity and 
mortality in diabetic patients. But it has one major setback which is deficiency of vitamin B12, a preventable and 
very much recoverable condition if diagnosed at optimum time. This deficiency can lead in deterioration of 
already present peripheral neuropathy in diabetic patients. In order to differentiate vitamin B12 deficiency 
caused peripheral neuropathy and usual peripheral neuropathy caused by the diabetes itself a systemized and 
well performed study is required. So that a perfect estimate of the level of deficiency can be developed which 
leads to the development of B12-deficiency induced neuropathy. Vitamin B12 concentrations in blood are not 
very good predictors of B12 deficiency 5, as it is usually normal even in clinically diagnosed B12 deficiency 
patients. On the other hand mild decrease in concentration of B12 in serum does not establish its deficiency. For 
this purpose two specific tests have been developed which are more sensitive to B12 deficiency as compared to 
B12 concentration itself. Holotrancobalamin (holoTC) 6 is a biological fraction of vitamin B12 and 
methylmelonic acid (MMA), are two markers for the diagnosis of status of vitamin B12 7. 
Correlation between vitamin B12 deficiency and metformin use has been studied worldwide but there are very 
little evidence present about the level to which it is decreased and its clinical impact as changes in neurological 
status and peripheral neuropathy. Moreover this correlation has not been studies in our population that is why we 
are not only going to assess the correlation between long term metformin use but also going to assess whether 
this deficiency has any impact over neuropathy among patients being treated with metformin for type II diabetes 
mellitus. 
 
Materials and Methods: 
An observational, cross-sectional study was conducted in Department of Medicine, Nishtar Hospital Multan 
from March 2018 to September 2019. Study was conducted on consecutive patients with type 2 diabetes mellitus 
on drug treatment seen at outpatient department of Nishtar Hospital Multan. Ethical approval for this study was 
obtained from Hospital Ethics Committee. Ninety two patients were involved after getting informed consent. 
Sampling technique of Non probability consecutive sampling was used to collect the sample size. Sample was 
calculated using the reference study by AK Singh et al 8. Patients were excluded if they gave history of 
alcoholism, ongoing pregnancy, liver disease, renal disease, thyroid disorders or history suggestive of 
malabsorption disorders. Type 1 diabetes mellitus patients were also excluded from analysis. Patients were 
selected by adhering strictly to these inclusion and exclusion criteria. 
Most of the patients taking part in this study were on hypoglycemic drugs for their diabetes mellitus type II. 
Detailed drug history was obtained and diet history was recorded as well. Patients were divided into two groups; 
those on treatment with metformin were segregated as one group and others as the second group. Cumulative 
dosage of metformin and duration of the use of the drug was recorded.  
After detailed history and examination following parameters were measured and recorded in the form of a 
performed performa; HbA1c, body mass index and blood pressure. Deficiency for vitamin B12 was assessed by 
using electro-chem-iluminescence immunoassay method. Samples for serum levels were kept for no more than 8 
hours and at a temperature range of 15 to 30o C. B12 levels were categorized as normal (>220pg/ml), possibly 
deficient (150 to 220 pg/ml) and definitely deficient (<150pg/ml). 
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Standard neurological examination was performed on all the patients who took part in study including, deep 
tendon reflexes, tone and power of the muscles and sensory function. At the end of all the procedures of history, 
general physical examination and standard neurological examination, the resultant outcome of neuropathy was 
assessed and was classified by using Toronto clinical scoring system by the researcher himself.  Gradation of the 
patients was carried out on the basis of score and grades were described as 0 to 5= No neuropathy, 6 to 9 mild 
neuropathy, 10 to 12 moderate neuropathy and greater than 12 as severe neuropathy. All the data was subjected 
to statistical analysis using computer software SPSS version 23. Continuous variables were analyzed by their 
mean and standard deviation while quantitative variables were analyzed by frequency and percentages. Chi 
square test was applied and P value less than or equal to 0.05 was taken as significant. 
 
Results: 
Mean age, weight, HbA1c, Mean blood pressure, hemoglobin and Mean Corpuscular Volume were 
42.87±10.07years, 58.32±13.84kg, 7.90±0.60, 124.96±7.30mmHg, 12.07±2.91mg/dl and 91.85±11.31 fl in 
metformin group; and 46.82±9.18years, 62.31±14.31kg, 8.04±.65, 126.10±6.22mmHg, 12.15±2.89mg/dl and 
92.15±11.23 fl in Non-metformin group. Both the groups were comparable. The patients who were 
simultaneously using insulin were 13 (24.5%) in metformin group and 19 (48.7%) in non-metformin group. The 
difference was statistically significant (p=0.016). (Table-I) 
Mean Serum B-12 levels were 378.42±161.27 pg/ml and 488.90±147.02 pg/ml in metformin and non-metformin 
groups, respectively. The difference was statistically significant (p=0.001). The patients who were possibly 
deficient and definitely deficient were 15 (28.30%) and 5 (9.43%) in metformin group and were significantly 
more (p=0.006) than non-metformin group i.e. 4 (10.26%) and 0. (Table-II) 
The mean Toronto Neuropathy Score was statistically different (p<0.001) between metformin group (6.03±1.73) 
and non-metformin group (4.13±1.75). The patients who had mild neuropathy and moderate neuropathy were 23 
(43.39%) and 5 (9.43%) in metformin group, while 6 (15.38%) and 2 (5.13%) in non-metformin group. 
Statistically, both the groups were significantly different (p=0.005). (Table-II) 
 
Table-I 
Baseline Variables 
Variable Metformin 
N=53 
Non-metformin 
N=39 
p-value 
Age (Years) 42.87±10.07 46.82±9.18 .057 
Male n (%) 44 (83) 33 (84.6) .838 
Weight (Kg) 58.32±13.84 62.31±14.31 .182 
HbA1c 7.90±0.60 8.04±.65 .280 
Mean blood pressure (mmHg) 124.96±7.30 126.10±6.22 .433 
Hemoglobin (mg/dl) 12.07±2.91 12.15±2.89 .898 
Mean Corpuscular Volume (fl) 91.85±11.31 92.15±11.23 .898 
Parallel Therapy 
Insulin n (%) 13 (24.5) 19 (48.7) .016 
Sulfonylureas n (%) 39 (73.6) 33 (84.6) .205 
Pioglitazone n (%) 21 (39.6) 14 (35.9) .716 
Variables are mentioned as mean ± S.D or number (percentage); Independent t test and chi-square test was 
applied. 
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Table-II 
Vitamin B-12 level and Toronto Clinical Neuropathy Score 
Variable Metformin Non-Metformin p-value 
Serum B-12 (pg/ml) 378.42±161.27 488.90±147.02 0.001 
Possible deficiency N (%) 15 (28.30) 4 (10.26) 0.006 
Definite Deficiency N (%) 5 (9.43) 0 (0) 
Toronto Neuropathy Score 6.03±1.73 4.13±1.75 <0.001 
No Neuropathy N (%) 25 (47.17) 31 (79.49)  
0.005 Mild Neuropathy N (%) 23 (43.39) 6 (15.38) 
Moderate Neuropathy N (%) 5 (9.43) 2 (5.13) 
Variables are mentioned as mean ± S.D or number (percentage); Independent t test and Fischer exact test was 
applied.  
 
Discussion: 
In this study results are in favor of the notion that metformin use in the treatment of type II diabetes mellitus 
does result in lowering the serum vitamin B12 levels. Peripheral neuropathy was also evidently more in the 
metformin users and was associated with lower levels of vitamin B12 in serum.   
Previously numerous studies have gave the evidence of lowering of vitamin B12 in people who use metformin 
for longer of duration of time 9,10,11,12,13 and a few case reports 14, 15 have also gave the evidence of association of 
increased incidence of neuropathy with low levels of B12 in serum and metformin use chronically. In a study 
18% of patients in metformin group had the evidence of low B12 levels as compared to the placebo group 10. 
Another retrospective study gave almost similar results in which 13 % patients with chronic use of metformin 
had the evidence of deficiency of vitamin B12 and 5.6% of the patients were definitely deficient in their serum 
levels of vitamin B12 (<150 pg/ml) 9. A cross sectional study in the region of Canada 12 and Hong Kong 11 
showed similar results to our study as they also observed deficiency of vitamin B12 in metformin user diabetic 
of type two diabetes mellitus as 31% and 37% respectively.  
Mechanism by which B12 deficiency occurs has been shown to involve calcium dependent ileal membrane 
antagonism, which results in low levels of serum B12 and malabsorption of B12 from lumen by chronic use of 
metformin. This effect can be reversed by the use of calcium as has been reported in recent studies 16. A Chinese 
case control study reported that not only long term use of metformin can cause vitamin B12 deficiency but its 
higher doses can have the similar effects irrespective of the presence of other clinical variables 17. A diabetes 
prevention program outcome study has given similar results to our study stating that metformin use not only 
lowers serum B12 level but also can cause its complications, like anemia (pernicious anemia) 18. A meta-analysis 
performed recently has demonstrated a close relation between chronic metformin use and low levels of vitamin 
B12 in serum of patients with type two diabetes mellitus 19. All of these studies have suggested that early 
detection of serum B12 deficiency is required in long term users of metformin as vitamin B12 deficiency can 
lead to serious complications like anemia and also can precipitate neuropathic effect of diabetes mellitus. 
 
Conclusion: 
At the end of this study conclusion can be made that metformin use for type II diabetes mellitus is strongly 
associated with vitamin B12 deficiency and worsening of already susceptible neuropathy. Suggestions can be 
made that vitamin B12 levels should be assessed in patients with long term metformin use so that hazardous 
increase of risk among these patients can be prevented. 
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